Sagent Pharmaceuticals Inc (SGNT) 27.75 $SGNT
Sagent Pharmaceuticals Sets Date and Time for Release of Fourth Quarter and Full Year 2014 Financial Results
GlobeNewswire - Thu Feb 12, 7:01AM CST
Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced that it will release financial results for the 2014 fourth quarter and full year pre-market on Thursday, February 19, 2015 and will host a teleconference and webcast at 9 a.m. ET to review the results.
SGNT: 27.75 (-0.41)
InsiderInsights.com Daily Round Up 1/28/15: FDO, WIA, EFOI, ASPX
InsiderInsights - at Seeking Alpha - Thu Jan 29, 9:39AM CST
EFOI: 4.60 (+0.44), RNST: 27.87 (+0.28), ASPX: 65.76 (+2.76), FDO: 77.86 (+0.31), SHLD: 35.70 (+2.32), SNI: 73.00 (+0.39), ADBE: 76.51 (+1.92), VSTM: 7.93 (-0.44), ALDR: 26.06 (+0.18), ALNY: 95.54 (+1.67), SSP: 20.91 (+0.47), SGNT: 27.75 (-0.41), MA: 87.14 (-0.38), WIA: 11.49 (-0.03), CRM: 62.85 (+1.59), SCHW: 29.13 (-0.83)
InsiderInsights.com Daily Round Up 1/26/15: THRM, FXCM, OPK, TCBI
InsiderInsights - at Seeking Alpha - Wed Jan 28, 3:00AM CST
AZZ: 44.86 (+0.22), IGTE: 39.53 (+0.62), BALT: 1.74 (+0.09), EGBN: 36.43 (-0.31), FXCM: 2.21 (-0.01), TCBI: 48.51 (+0.81), THRM: 41.21 (+0.38), VEEV: 30.12 (+0.17), VSAR: 18.04 (-0.55), PN: 13.35 (-0.14), LNKD: 269.00 (+1.83), OPK: 13.80 (-0.28), NERV: 4.68 (+0.09), CAS: 6.14 (-0.01), SGNT: 27.75 (-0.41), ARIA: 7.35 (+0.45), TWTR: 48.50 (+0.55), BKE: 49.59 (-0.16)
Commit To Buy Sagent Pharmaceuticals At $22.50, Earn 10.8% Annualized Using Options
at The Street - Mon Jan 26, 10:45AM CST
Investors considering a purchase of Sagent Pharmaceuticals Inc shares, but tentative about paying the going market price of $26.23/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting...
SGNT: 27.75 (-0.41)
InsiderInsights.com Daily Round Up 1/15/15: ETE, OVAS, TWMC, GPC
InsiderInsights - at Seeking Alpha - Thu Jan 15, 11:44PM CST
TWMC: 3.67 (+0.12), OVAS: 44.32 (+0.87), GPC: 97.01 (+0.22), GNCMA: 14.49 (-0.14), UPLD: 7.22 (-0.02), ETE: 59.75 (+1.45), FUND: 7.47 (+0.05), SRE: 105.56 (-1.11), GOOG: 549.01 (+6.08), MFRM: 62.22 (-0.12), TNET: 36.49 (+0.76), BH: 416.41 (-1.55), WIW: 11.29 (unch), JPM: 59.67 (+0.10), LNKD: 269.00 (+1.83), CDNA: 6.30 (-0.14), SGNT: 27.75 (-0.41), AAVL: 36.29 (+0.01), ALCO: 45.40 (+1.44)
Sagent Pharmaceuticals is in Talks with Potential Targets
at The Street - Wed Jan 14, 7:31AM CST
Buys in the injectables space are on the table for the pharmaceutical company.
SGNT: 27.75 (-0.41)
Sagent Pharmaceuticals to Present at 33rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Thu Jan 08, 3:29PM CST
Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced that it will present at the 33 Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2015 at 7:30 a.m. PT (9:30 a.m. CT/10:30 a.m. ET). A live webcast of the conference will be available on the Company's website at: http://investor.sagentpharma.com/events.cfm. In order to register and download any necessary software, please log on 10 minutes prior to the start of the webcast.
JPM: 59.67 (+0.10), SGNT: 27.75 (-0.41)
Sagent Pharmaceuticals Announces the Launch of Colistimethate for Injection, USP
GlobeNewswire - Tue Dec 30, 7:36AM CST
Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the launch of Colistimethate for Injection, USP, an anti-infective, in a preservative-free glass vial. According to IMS, for the 12 months ending October 2014, the US market for Colistimethate approximated $12 million. As with all products in Sagent's portfolio, Colistimethate features Sagent's PreventIV Measures packaging and labeling, designed to help reduce medication errors.
SGNT: 27.75 (-0.41)
Sagent Pharmaceuticals (SGNT) in Focus: Stock Falls 7.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 7:34AM CST
Shares of Sagent Pharmaceuticals (SGNT) fell over 7% on the day. This continues the most recent downtrend for SGNT, as the stock is down over 17% in the past one month time frame. This recent price action is discouraging, so make sure to keep a close watch on this firm in the near future.
SGNT: 27.75 (-0.41), IG: 10.57 (-0.12)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 11:46AM CST
PTRY: 36.72 (+0.05), VIP: 5.37 (+0.51), CCM: 6.84 (-0.10), HGSH: 3.05 (-0.13), CLF: 7.00 (+0.35), ASPX: 65.76 (+2.76), SN: 15.21 (-0.12), NVGN: 2.79 (+0.17), NYNY: 6.33 (+0.06), FVE: 3.74 (+0.18), DRIV: 25.99 (+0.06), SGNL: 3.91 (+2.15), RT: 6.40 (+0.20), SFY: 2.91 (+0.26), VOLC: 17.98 (+0.03), WRES: 1.27 (+0.01), SGNT: 27.75 (-0.41), BBLU: 1.26 (+0.09), POZN: 6.95 (+0.15), XNCR: 15.47 (-0.22)
Ryanair Holdings (RYAAY) Jumps: Stock Adds 7.2% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 05, 8:11AM CST
Ryanair Holdings plc (RYAAY) was a big mover last session, as the company saw its shares rise over 7% on the day.
LCI: 57.78 (-0.91), RYAAY: 61.46 (-2.33), SGNT: 27.75 (-0.41), IG: 10.57 (-0.12)
Otonomy (OTIC) Jumps: Stock Adds 5.7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 02, 8:11AM CST
Otonomy, Inc. (OTIC) was a big mover last session, as the company saw its shares rise roughly 6% on the day.
LCI: 57.78 (-0.91), SGNT: 27.75 (-0.41), IG: 10.57 (-0.12), OTIC: 31.14 (+0.13)
Sagent (SGNT) Sees Hammer Chart Pattern: Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 21, 7:56AM CST
Sagent (SGNT) Sees Hammer Chart Pattern: Time to Buy?
SGNT: 27.75 (-0.41)
Sagent Chairman and CEO Jeff Yordon Inducted Into the UIC Chicago Area Entrepreneurship Hall of Fame
GlobeNewswire - Fri Nov 07, 8:35AM CST
Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) ("Sagent"
, a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced that Jeff Yordon, the company's Chairman and Chief Executive Officer, has been inducted into the UIC Chicago Area Entrepreneurship Hall of Fame.
SGNT: 27.75 (-0.41)
Sagent Pharmaceuticals' (SGNT) CEO Jeff Yordon on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 04, 8:09PM CST
SGNT: 27.75 (-0.41)
Sagent Pharmaceuticals (SGNT) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Nov 04, 7:55AM CST
SGNT: 27.75 (-0.41)
Sagent Pharmaceuticals beats by $0.12, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 6:06AM CST
SGNT: 27.75 (-0.41)
Sagent Pharmaceuticals Reports Third Quarter 2014 Financial Results
GlobeNewswire - Tue Nov 04, 6:00AM CST
Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced financial results for the quarter ended September 30, 2014.
SGNT: 27.75 (-0.41)
Sagent Pharma reports November 4
Seeking Alpha - at Seeking Alpha - Fri Oct 24, 3:07PM CDT
SGNT: 27.75 (-0.41)
Sagent Pharmaceuticals Sets Date and Time for Release of Third Quarter 2014 Financial Results
GlobeNewswire - Fri Oct 24, 3:00PM CDT
Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced that it will release financial results for the 2014 third quarter pre-market on Tuesday, November 4, 2014 and will host a teleconference and webcast at 9 a.m. ET to review the results.
SGNT: 27.75 (-0.41)
Sagent Pharmaceuticals Sets Date and Time for Release of Fourth Quarter and Full Year 2014 Financial Results
GlobeNewswire - Thu Feb 12, 7:01AM CST
Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced that it will release financial results for the 2014 fourth quarter and full year pre-market on Thursday, February 19, 2015 and will host a teleconference and webcast at 9 a.m. ET to review the results.
SGNT: 27.75 (-0.41)
InsiderInsights.com Daily Round Up 1/28/15: FDO, WIA, EFOI, ASPX
InsiderInsights - at Seeking Alpha - Thu Jan 29, 9:39AM CST
EFOI: 4.60 (+0.44), RNST: 27.87 (+0.28), ASPX: 65.76 (+2.76), FDO: 77.86 (+0.31), SHLD: 35.70 (+2.32), SNI: 73.00 (+0.39), ADBE: 76.51 (+1.92), VSTM: 7.93 (-0.44), ALDR: 26.06 (+0.18), ALNY: 95.54 (+1.67), SSP: 20.91 (+0.47), SGNT: 27.75 (-0.41), MA: 87.14 (-0.38), WIA: 11.49 (-0.03), CRM: 62.85 (+1.59), SCHW: 29.13 (-0.83)
InsiderInsights.com Daily Round Up 1/26/15: THRM, FXCM, OPK, TCBI
InsiderInsights - at Seeking Alpha - Wed Jan 28, 3:00AM CST
AZZ: 44.86 (+0.22), IGTE: 39.53 (+0.62), BALT: 1.74 (+0.09), EGBN: 36.43 (-0.31), FXCM: 2.21 (-0.01), TCBI: 48.51 (+0.81), THRM: 41.21 (+0.38), VEEV: 30.12 (+0.17), VSAR: 18.04 (-0.55), PN: 13.35 (-0.14), LNKD: 269.00 (+1.83), OPK: 13.80 (-0.28), NERV: 4.68 (+0.09), CAS: 6.14 (-0.01), SGNT: 27.75 (-0.41), ARIA: 7.35 (+0.45), TWTR: 48.50 (+0.55), BKE: 49.59 (-0.16)
Commit To Buy Sagent Pharmaceuticals At $22.50, Earn 10.8% Annualized Using Options
at The Street - Mon Jan 26, 10:45AM CST
Investors considering a purchase of Sagent Pharmaceuticals Inc shares, but tentative about paying the going market price of $26.23/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting...
SGNT: 27.75 (-0.41)
InsiderInsights.com Daily Round Up 1/15/15: ETE, OVAS, TWMC, GPC
InsiderInsights - at Seeking Alpha - Thu Jan 15, 11:44PM CST
TWMC: 3.67 (+0.12), OVAS: 44.32 (+0.87), GPC: 97.01 (+0.22), GNCMA: 14.49 (-0.14), UPLD: 7.22 (-0.02), ETE: 59.75 (+1.45), FUND: 7.47 (+0.05), SRE: 105.56 (-1.11), GOOG: 549.01 (+6.08), MFRM: 62.22 (-0.12), TNET: 36.49 (+0.76), BH: 416.41 (-1.55), WIW: 11.29 (unch), JPM: 59.67 (+0.10), LNKD: 269.00 (+1.83), CDNA: 6.30 (-0.14), SGNT: 27.75 (-0.41), AAVL: 36.29 (+0.01), ALCO: 45.40 (+1.44)
Sagent Pharmaceuticals is in Talks with Potential Targets
at The Street - Wed Jan 14, 7:31AM CST
Buys in the injectables space are on the table for the pharmaceutical company.
SGNT: 27.75 (-0.41)
Sagent Pharmaceuticals to Present at 33rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Thu Jan 08, 3:29PM CST
Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced that it will present at the 33 Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2015 at 7:30 a.m. PT (9:30 a.m. CT/10:30 a.m. ET). A live webcast of the conference will be available on the Company's website at: http://investor.sagentpharma.com/events.cfm. In order to register and download any necessary software, please log on 10 minutes prior to the start of the webcast.
JPM: 59.67 (+0.10), SGNT: 27.75 (-0.41)
Sagent Pharmaceuticals Announces the Launch of Colistimethate for Injection, USP
GlobeNewswire - Tue Dec 30, 7:36AM CST
Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the launch of Colistimethate for Injection, USP, an anti-infective, in a preservative-free glass vial. According to IMS, for the 12 months ending October 2014, the US market for Colistimethate approximated $12 million. As with all products in Sagent's portfolio, Colistimethate features Sagent's PreventIV Measures packaging and labeling, designed to help reduce medication errors.
SGNT: 27.75 (-0.41)
Sagent Pharmaceuticals (SGNT) in Focus: Stock Falls 7.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 7:34AM CST
Shares of Sagent Pharmaceuticals (SGNT) fell over 7% on the day. This continues the most recent downtrend for SGNT, as the stock is down over 17% in the past one month time frame. This recent price action is discouraging, so make sure to keep a close watch on this firm in the near future.
SGNT: 27.75 (-0.41), IG: 10.57 (-0.12)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 11:46AM CST
PTRY: 36.72 (+0.05), VIP: 5.37 (+0.51), CCM: 6.84 (-0.10), HGSH: 3.05 (-0.13), CLF: 7.00 (+0.35), ASPX: 65.76 (+2.76), SN: 15.21 (-0.12), NVGN: 2.79 (+0.17), NYNY: 6.33 (+0.06), FVE: 3.74 (+0.18), DRIV: 25.99 (+0.06), SGNL: 3.91 (+2.15), RT: 6.40 (+0.20), SFY: 2.91 (+0.26), VOLC: 17.98 (+0.03), WRES: 1.27 (+0.01), SGNT: 27.75 (-0.41), BBLU: 1.26 (+0.09), POZN: 6.95 (+0.15), XNCR: 15.47 (-0.22)
Ryanair Holdings (RYAAY) Jumps: Stock Adds 7.2% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 05, 8:11AM CST
Ryanair Holdings plc (RYAAY) was a big mover last session, as the company saw its shares rise over 7% on the day.
LCI: 57.78 (-0.91), RYAAY: 61.46 (-2.33), SGNT: 27.75 (-0.41), IG: 10.57 (-0.12)
Otonomy (OTIC) Jumps: Stock Adds 5.7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 02, 8:11AM CST
Otonomy, Inc. (OTIC) was a big mover last session, as the company saw its shares rise roughly 6% on the day.
LCI: 57.78 (-0.91), SGNT: 27.75 (-0.41), IG: 10.57 (-0.12), OTIC: 31.14 (+0.13)
Sagent (SGNT) Sees Hammer Chart Pattern: Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 21, 7:56AM CST
Sagent (SGNT) Sees Hammer Chart Pattern: Time to Buy?
SGNT: 27.75 (-0.41)
Sagent Chairman and CEO Jeff Yordon Inducted Into the UIC Chicago Area Entrepreneurship Hall of Fame
GlobeNewswire - Fri Nov 07, 8:35AM CST
Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) ("Sagent"
, a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced that Jeff Yordon, the company's Chairman and Chief Executive Officer, has been inducted into the UIC Chicago Area Entrepreneurship Hall of Fame. SGNT: 27.75 (-0.41)
Sagent Pharmaceuticals' (SGNT) CEO Jeff Yordon on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 04, 8:09PM CST
SGNT: 27.75 (-0.41)
Sagent Pharmaceuticals (SGNT) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Nov 04, 7:55AM CST
SGNT: 27.75 (-0.41)
Sagent Pharmaceuticals beats by $0.12, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 6:06AM CST
SGNT: 27.75 (-0.41)
Sagent Pharmaceuticals Reports Third Quarter 2014 Financial Results
GlobeNewswire - Tue Nov 04, 6:00AM CST
Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced financial results for the quarter ended September 30, 2014.
SGNT: 27.75 (-0.41)
Sagent Pharma reports November 4
Seeking Alpha - at Seeking Alpha - Fri Oct 24, 3:07PM CDT
SGNT: 27.75 (-0.41)
Sagent Pharmaceuticals Sets Date and Time for Release of Third Quarter 2014 Financial Results
GlobeNewswire - Fri Oct 24, 3:00PM CDT
Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced that it will release financial results for the 2014 third quarter pre-market on Tuesday, November 4, 2014 and will host a teleconference and webcast at 9 a.m. ET to review the results.
SGNT: 27.75 (-0.41)
